Changes in prostate orientation due to removal of a Foley catheter by Litzenberg, Dale W. et al.
Changes in prostate orientation due to removal of a Foley catheter
Dale W. Litzenberga)
Radiation Oncology, University of Michigan, Ann Arbor, MI 48109-5010, USA
Daniel G. Muenz
Department of Biostatistics, University of Michigan, Ann Arbor, MI 48109, USA
Paul G. Archer, and William C. Jackson
Radiation Oncology, University of Michigan, Ann Arbor, MI 48109-5010, USA
Daniel A. Hamstra
Radiation Oncology, Beaumont Health System, Royal Oak, MI 48073, USA
Jason W. Hearn
Radiation Oncology, University of Michigan, Ann Arbor, MI 48109-5010, USA
Matthew J. Schipper
Departments of Radiation Oncology and Biostatistics, University of Michigan, Ann Arbor, MI 48109, USA
Daniel E. Spratt
Radiation Oncology, University of Michigan, Ann Arbor, MI 48109-5010, USA
(Received 4 October 2017; revised 31 January 2018; accepted for publication 31 January 2018;
published 25 March 2018)
Purpose: Investigate the impact on prostate orientation caused by use and removal of a Foley cathe-
ter, and the dosimetric impact on men prospectively treated with prostate stereotactic body radiother-
apy (SBRT).
Methods: Twenty-two men underwent a CT simulation with a Foley in place (FCT), followed imme-
diately by a second treatment planning simulation without the Foley (TPCT). The change in prostate
orientation was determined by rigid registration of three implanted transponders between FCT and
TPCT and compared to measured orientation changes during treatment. The impact on treatment
planning and delivery was investigated by analyzing the measured rotations during treatment relative
to both CT scans, and introducing rotations of 15° in the treatment plan to determine the maximum
impact of allowed rotations.
Results: Removing the Foley caused a statistically significant prostate rotation (P < 0.0028) com-
pared to normal biological motion in 60% of patients. The largest change in rotation due to removing
a Foley occurs about the left–right axis (tilt) which has a standard deviation two to five times larger
than changes in rotation about the Sup-Inf (roll) and Ant-Post (yaw) axes. The change in tilt due to
removing a Foley for prone and supine patients was 1.1°  6.0° and 0.3°  7.4°, showing no
strong directional bias. The average tilt during treatment was 1.6°  7.1° compared to the TPCT
and would have been 2.0°  7.1° had the FCT been used as the reference. The TPCTwas a better
or equivalent representation of prostate tilt in 82% of patients, vs 50% had the FCT been used for
treatment planning. However, 92.7% of fractions would still have been within the 15° rotation limit
if only the FCTwere used for treatment planning. When rotated 15°, urethra V105% = 38.85Gy < 20%
was exceeded in 27% of the instances, and prostate (CTV) coverage was maintained above
D
95%
> 37 Gy in all but one instance.
Conclusions: Removing a Foley catheter can cause large prostate rotations. There does not appear to
be a clear dosimetric benefit to obtaining the CT scan with a Foley catheter to define the urethra given
the changes in urethral position from removing the Foley catheter. If urethral sparing is desired
without the use of a Foley, utilization of an MRI to define the urethra may be necessary, or a
pseudo-urethral planning organ at risk volume (PRV) may be used to limit dosimetric hot spots.
© 2018 American Association of Physicists in Medicine [https://doi.org/10.1002/mp.12830]
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1. INTRODUCTION
There has been an increased utilization of hypofractionated
radiotherapy for prostate cancer, and there is growing evidence
for the safety and efficacy of more extreme hypofractionation
schedules, such as stereotactic body radiotherapy (SBRT).1–5
With these ultra-hypofractionated schedules, there has been
concern regarding the potential for increased toxicity, and
extra measures are being investigated to minimize these poten-
tial side effects.1,6,7
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Prostate SBRT has been referred to by some as virtual high
dose-rate (HDR) brachytherapy, due to the analogous high dose
per fraction.8 Brachytherapy has been associated with the
potential for increased genitourinary toxicity and risk for ure-
thral structures compared to fractionated external beam radio-
therapy, and similar concerns exist with prostate SBRT. To
mitigate this risk, many investigators have utilized a Foley
catheter during CT simulation to aid in delineating the
urethra,9–11 given that the prostatic urethra is not readily visible
during standard CT imaging. However, given the known risks
of repeat Foley placement and the discomfort to the patient,
many centers perform two simulation scans, one with the Foley
catheter (FCT) and one without the Foley catheter as their treat-
ment planning CT scan (TPCT). This allows for the TPCT to
emulate the daily treatments without the Foley catheter, but still
obtain the anatomic information on the location of the urethra.
While the prostate translations from a retrograde urethro-
gram have been previously studied and found to be clinically
insignificant,12 the motion and dosimetric impact of placement
and removal of the Foley have not been reported. Previous stud-
ies have investigated the anatomic deformations of the prostate
due to differential rectal and bladder filling over the course of
therapy and found the variation compared to the treatment plan-
ning CT to be small (standard deviation <0.1 cm) compared to
inter- and intrafraction translational motion.13–15 Other studies
have measured inter- and intrafraction prostate rotations16–18
and the dosimetric impact of rotations.19 Many strategies have
been investigated to manage prostate rotations through appro-
priate PTV margins,20–22 motion management devices,23 rota-
tion compensations with the table, collimator or gantry,24,25
and adaptive replanning.21,26,27
Given the risks of catheter placement, including urinary
tract infections and discomfort, we utilized data from a multi-
institutional prostate SBRT study conducted from 2011 to
2013 to better determine the impact and benefit of the Foley
catheter placement. The goal of the project was to investigate
whether two CT simulation scans were necessary and if treat-
ment planning could be performed on the FCT alone, or on
the TPCTwithout a Foley at all. Reducing the number of CT
scans has benefits for more efficient use of departmental
resources, as it would save time and reduce imaging dose to
the patient. Likewise, if a Foley were not needed, it would
additionally save time and patient discomfort.
2. MATERIALS AND METHODS
2.A. Protocol eligibility
Of the 68 patients enrolled in the multicenter trial, 22
patients were consented to the IRB-approved prostate SBRT
study at our institution that had both the FCT and the TPCT
available (NCT01288534). The clinical results of this trial
were previously reported.28 All patients were 18 yr of age or
older with a histologically confirmed diagnosis of adenocar-
cinoma of the prostate within 180 days of enrollment.
Patients with PSA values of <=15 ng/ml for Gleason scores
of <=6, and <=10 ng/ml for Gleason score of 7 were eligible
with tumor staging of T2b or less, and no plan for androgen
deprivation therapy. Exclusion criteria included contraindica-
tions for electromagnetic tracking, implanted cardiac devices,
metastatic disease to the lymph nodes, previous radiation,
surgery, chemotherapy, or androgen deprivation therapy for
prostate cancer, any significant urinary obstructive symp-
toms, and prostate volume of >100 cm3.
2.B. Simulation and treatment planning
Transponders were implanted a minimum of 6 days before
simulation.29 Patients took milk of magnesia the night before
and on the morning of simulation and each treatment frac-
tion. Additionally, a fleet’s enema was self-administered
2–3 h before simulation and each treatment. Two CT scans
were obtained in either the supine or prone position with a
0.1-cm image thickness. The first CT scan was obtained with
a Foley catheter in place (FCT). The Foley was then removed
with the patient on the CT couch and a second treatment plan-
ning CT (TPCT) scan was obtained, typically within 1–2 min
after the first scan. Eleven patients were CT scanned supine
with knee support, while another 11 were scanned prone on a
belly board. The intraprostatic urethra was contoured on the
FCT from 0.5 cm into the Foley balloon and down 0.5 cm
distal to the apex of the prostate. Deformations of the prostate
due to changes in rectal and bladder filling are small com-
pared to prostate motion.13,15 It is assumed that the deforma-
tion of the prostate and urethra are also small due to the
insertion and removal of a Foley catheter, which is a much
smaller geometric perturbation than rectal and bladder
changes. Consequently, the FCT and urethra were rigidly reg-
istered to the TPCT using fiducial markers (radiofrequency
transponders) within the prostate. The rigid registration trans-
formation was found with a standard least squares minimiza-
tion routine employing a singular value decomposition (SVD)
algorithm available in the UMPlan treatment planning system.
The CTV is defined as the prostate as contoured on the TPCT.
The prescription dose was 7.4 Gy/fraction 9 5 fractions
to a total dose of 37.0 Gy. The PTV was defined as the pros-
tate plus a uniform 0.3-cm margin. The PTV planning criteria
were D95% ≥ 37 Gy, V115% < 15% or 10 cc (whichever is
smaller), and Dmax < 120%. Hot spots within the prostatic
urethra were limited to Dmax ≤ 40.7 Gy (110%) and V105%
(38.85 Gy) ≤ 20%. Rectum constraints were Dmax ≤ 105%,
V100% < 2 cc, D90% ≤ 10%, D81% ≤ 20%, and D50% ≤ 50%.
Bladder constraints included Dmax ≤ 110% and V65% < 25%
or 50 cc (whichever is smaller).
2.C. Calculation of rotation from foley removal
The rigid-body registration transformation from the FCT to
the TPCTwas decomposed into translation and rotation compo-
nents and the rotations about the left–right axis (tilt), superior–
inferior axis (roll), and the anterior–posterior axis (yaw) were
determined from the rotation transformation matrix,
R ¼ RAPðuÞ  RSIð/Þ  RLRðhÞ; (1)
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where RLR(h) denotes a tilt rotation about the left–right, X,
axis by an angle h, RSI(/) denotes a roll rotation about the
superior–inferior, Y, axis, by an angle /, and RAP(φ) denotes
a yaw rotation about the anterior–posterior, Z, axis, by an
angle φ.
To determine if these angles were larger than would be
expected due to normal biological motion over the course of
1–2 min, real-time tracking data were used from the Calypso
System to obtain the distribution of normal biological rota-
tions over 1- and 2-min intervals for each patient. The change
in rotation of the prostate due to removing the Foley was then
compared to the patient’s distribution of normal biological
rotation to determine statistical significance. Through a
research agreement with Varian Medical Systems (Palo Alto,
CA, USA), tracking data, including the position of all three
beacons vs time (updated at 10 Hz), could be exported from
the tracking system. These tracking data were obtained for
each of the five treatment fractions for each patient and was
used to calculate the real-time rotation angles (10 Hz) of the
prostate, relative to the TPCT, during each treatment. This
was accomplished with a least squares minimization routine
using SVD to obtain the transformation between the mea-
sured beacon positions and the planned positions from the
TPTC. The transformation was then decomposed as shown in
Eq. (1) to obtain the measured rotations about each axis
every 0.1 s for each of the five fractions.
The distribution of changes in rotation expected due to
normal biological motion over 1 and 2 min intervals, Dh(t)Τ,
for each fraction were calculated as shown in Eq. (2).
DhðtÞT ¼ hðtÞ hðtTÞ where t[T¼ 1;2 minutes (2)
These two time intervals (T = 1 and 2 min) for orientation
changes due to normal biological motion were evaluated to test
the sensitivity of the results on time scales comparable to the
variation in time between the FCT and the TPCT. While the
rotations are measured in the TPCT frame, the change in rota-
tion calculated in Eq. (2), is the change during a single fraction
relative to the rotation at the beginning of that fraction. Conse-
quently, it represents only biological motion over a treatment
fraction. Any systematic changes from the orientation in the
TPCT scan are subtracted out. The change in rotation of the
prostate due to removing the Foley was then compared to the
histogram of changes in rotation due to normal biological
motion to determine the probability that the rotation due to
removing the Foley was just due to normal biological motion.
Because the statistical validity of adding histograms for all five
fractions, which may have different systematic offsets and
trends during each fraction, is questionable, the comparison was
made with just the first fraction of data and all five fractions of
data for each patient to test the sensitivity to this possible issue.
2.D. Determining preferred simulation CT (TPCT or
FCT)
In practice, the orientation of the prostate is difficult to
control, and statistically, it is possible that it might be equally
or adequately represented by the FCT, justifying a single CT
scan, albeit with a Foley in place. The tilt angle distributions
during treatment were determined from the real-time mea-
sured transponder data and the FCT-to-TPCT registration
angles, for each patient relative to the FCT and the TPCT. Ini-
tial and average measured tilt angles determined from the
real-time tracking data are relative to the TPCT. The FCT-to-
TPCT tilt value for each patient is determined by rigid regis-
tration. The FCT-to-TPCT tilt is added to these values to
obtain the average tilt of all fractions and the initial tilt of each
fraction relative to the FCT. (Here it is assumed that small
yaw and roll angles have minimal impact on clinical results.)
The average values of tilt relative to the FCT and to the TPCT
may then be compared to determine which is closest to zero.
Likewise, the initial rotation relative to the FCT and the
TPCT for each fraction may be compared to the tolerance.
Additionally, the number of fractions within the 15° toler-
ance used in the protocol may be compared for each patient
to the TPCT and the FCT orientation to determine the impact
on clinical workflow.
2.E. Dosimetric impact on the urethra and prostate
of the maximum allowed rotations
The potential dosimetric impact of rotations is evaluated
in the context of the tolerances set for the protocol, which are
TABLE I. Change in tilt, roll, and yaw angles due to removing a Foley cathe-
ter, found from rigidly registering FCT to TPCT.
Pat ID φ (Roll)° / (Yaw)° h (Tilt)°
p1 1.0 1.5 7.2
p2 0.5 5.8 12.2
p3 3.3 8.4 3.7
p4 1.9 0.8 5.9
p5 2.9 0.5 5.0
p6 0.3 0.2 1.5
p7 1.9 0.7 4.7
p8 1.5 0.2 2.1
p9 1.0 1.1 5.2
p10 1.6 2.9 6.6
p11 3.5 1.0 2.2
Ave 1.0 1.7 1.1
r 1.8 2.9 6.0
s1 0.4 0.0 0.1
s2 2.1 0.1 0.3
s3 0.8 0.8 6.1
s4 1.2 0.0 0.1
s5 3.3 4.7 20.1
s6 1.0 0.0 0.3
s7 1.7 2.6 4.3
s8 0.2 0.5 1.2
s9 0.4 0.2 5.9
s10 0.4 0.3 7.1
s11 0.5 0.5 0.3
Ave 0.1 0.1 0.3
r 1.5 1.7 7.4
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easily monitored and enforced at the beginning of each treat-
ment fraction. For this protocol a rotational limit of 15°
was used and sets the de facto limit of dosimetric variation
that’s acceptable due to inter- and intrafractional rotational
setup errors. The functionality within the UMPlan treatment
planning system for evaluating rotational variations has been
previously described and reported by Amro.19 The prostate
has been shown to behave as a reasonably rigid object in the
sense that geometric variations due to deformation are small
compared to organ motion.13,15 Because the urethra passes
through the prostate, and moves with the prostate, it is rea-
sonable to infer that the same is true of the urethra and that
dosimetric variations due to deformation are second-order
compared to dosimetric variations caused by motion and
rotation. To assess the impact of the largest rotations allowed
by the protocol these new DVH curves were evaluated
against the protocol constrains, PTV D95%, and urethra
Dmax < 40.7 Gy and V105% = 38.85 Gy < 20%, and compared
(rotated minus planned DVH values) to the values from the
original treatment plans. The changes in CTV D95% and CTV
D99% were also evaluated to assess the adequacy of the PTV
margin.
3. RESULTS
3.A. Impact of foley removal on prostate rotation
Table I shows the tilt, roll, and yaw angles found by
Eq. (1), in registering FCT toTPCT. Note that all angles aver-
age within 0.3°  7.4° of zero for supine patients and
1.1°  6.0° of zero for prone patients indicating no strong
preferred rotational direction change when removing the
Foley. Also note, that the standard deviation of the tilt is more
than double that of the roll and yaw. Consequently, this work
focused on results related to the tilt angle.
The measured real-time tilt angle of the prostate relative to
the TPCT and FCT over the course of each fraction is shown
in Fig. 1 for each patient. Figure 2 shows the histograms of
all changes in tilt over a sliding 2-min interval during all five
fractions of treatment [as calculated by Eq. (2)], along with
FIG. 1. Tilt angle in degrees about the left–right axis vs time relative to the TPCT (solid line at zero degrees) for each fraction of each patient. The dashed line
shows the tilt of the prostate in the FCT relative to the TPCT. The top two rows show prone patients p1 through p11, while the bottom two rows show supine
patients s1 through s11. [Color figure can be viewed at wileyonlinelibrary.com]
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the observed change in tilt from the FCT to the TPCT
(dashed line). The histograms were integrated to generate
cumulative density functions and the probability of the
change in tilt observed between the FCT and the TPCT for
each patient was determined for time intervals of 1 and
2 min, as well as for the first fraction and all five fractions, as
shown in Table II.
Figure 2 illustrates that many of the tilt changes caused by
removing the Foley are much larger than would be expected
from normal biological motion. For the prone patients,
regardless of the time interval or the number of fractions, 8 of
11 patients are outside the 95% confidence interval (i.e.,
<2.5%, >97.5%). If the changes in tilt due to removing
the Foley were no different from normal biological motion,
the probability of 8 of 11 occurrences would be 5.6 9 109,
assuming a binomial distribution. Likewise, 5 of 11
supine patients are outside the 95% confidence interval. If
the changes in tilt due to removing the Foley were no
different from normal biological motion, the probability of 5
of 11 occurrences would be 1.1 9 104. Removing the Foley
caused a statistically significant prostate rotation (P <
0.0028) compared to normal biological motion in 60% of
patients.
3.B. Rotations during treatment relative to TPCT
and FCT
Figure 1 shows the tilt angle vs time for each fraction of
each patient, relative to the TPCT and the FCT. These data
are histogrammed in Fig. 3 which also shows the percentile
of tilt angles during treatment that are less than the tilt during
the FCT and TPCT (i.e., the area under the histogram in
Fig. 3 to the left of the red or blue line showing the FCT or
TPCT tilt angle). Eleven patients were outside the 95%
FIG. 2. Histograms of the changes in tilt over a sliding 120-s interval relative to the TPCT and the FCT (vertical mark, column 4 from Table II) for all five fractions.
[Color figure can be viewed at wileyonlinelibrary.com]
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confidence interval (i.e., <2.5% or >97.5%) relative to the
FCT, vs nine patients for the TPCT, and nine patients are
equally or better represented by the orientation of the FCT.
Figure 4 shows the initial measured tilt relative to the
TPCT and FCT for each fraction. The average tilt for all frac-
tions and all patients relative to the TPCT are, 3.2°  6.5°,
0.1°  7.3°, and 1.6°  7.1° for prone, supine, and all
patients, and relative to the FCT they are 4.3°  6.5°,
0.4°  7.3°, and 2.0°  7.1°, respectively. These average
values are all within the commonly used rotational limits of
10°, which is the default value on the tracking system, or
15°, in the case of this protocol.20 Four patients had eight
fractions with initial rotations out of the 15° tolerance rela-
tive to the FCT, while only one patient had one fraction out
of tolerance relative TPCT.
3.C. Dosimetric impact on the urethra and prostate
of the maximum allowed rotations
The dosimetric impact of 15° rotations relative to the
TPCT on urethra and the prostate are shown in Figs. 5 and 6,
respectively. The urethra Dmax <= 110% = 40.7 Gy criteria
was met for all patients at both +15° and 15° [Fig. 5(a)],
increasing by 0.66%, from 39.4  0.5 Gy to 39.6  0.5 Gy.
However, the urethra V105% = 38.85 Gy < 20% planning con-
straint increased from an average of 3.8  3.4% with no
rotations, to 14.4  9.4% at 15°, and to 17.6  10.5% at
+15° [Fig. 5(b)]. Nine patients exceeded V105% =
38.85 Gy < 20% when rotated 15°. Of the 44 dose calcula-
tions at +15° and 15° for the 22 patients, 12 (27%)
exceeded the V105% = 38.85 Gy < 20% planning constraint.
Ideally, the PTV expansion is large enough to maintain
adequate dosimetric coverage of the CTV under anticipated
distribution of translations, rotations, and deformations. At
the rotational limits of the protocol, the CTV (prostate) and
PTV coverage would vary as follows. The change in CTV
D99% relative to the prescription dose (37 Gy) is shown in
Fig. 6(a). The average changed by 2.1  4.0%, from
37.1  0.3 Gy to 36.3  1.0 Gy. CTV D95% which is used
to assess clinical acceptability, would be maintained with an
average reduction of only 0.2%, from CTV D95% of
37.6  0.3 Gy to 37.5  0.4 Gy as shown in Fig. 6(b). (In
only one instance (15° rotation for patient p2) did D95%
drop below 37 Gy to 36.6 Gy.) As seen in Fig. 6(c), the PTV
D95% coverage drops 3.5  1.6% from 37.2  0.3 Gy to
35.9  0.6 Gy.
4. DISCUSSION
It is clear that removing the Foley catheter can cause a sta-
tistically significant change in tilt of the prostate compared to
the normal biologically induced changes in prostate orienta-
tion. While the average tilt during treatment compared to the
TPCT (1.6°  7.1°) and FCT (2.0°  7.1°) are very simi-
lar and well within treatment tolerances, as expected the
TPCT is a better or equivalent representation of prostate tilt
in 18 of 22 patients, In contrast, the FCT is a better or equiva-
lent representation in only 11 of 22 patients. However, 92.7%
(102 of 110) of the fractions would still have initially been
within the 15° rotation limit if only the FCT were used for
treatment planning. Even when rotated 15°, the
V105% = 38.85 Gy < 20% constraint was only exceeded in
27% of the instances. In these instances, the value of
V105% = 38.85 Gy was <27%, with the exception of one patient
were it ranged from 44.6% to 55.5% depending on the sign
of the rotation. Importantly, dosimetric coverage of the pros-
tate was maintained above D95% > 37 Gy in all but one
instance for rotations of 15°. With only two patients averag-
ing <15° (15.1° and 15.6° for patients p4 and s5) over
the course of treatment relative to the FCT, loss of adequate
dosimetric coverage of the prostate does not appear to be an
issue if treatment planning were to be performed on the FCT.
If planning were to be done on a single CT scan without a
Foley, one strategy to avoid hot spots to the urethra would be
to define a generic disk-like planning organ at risk volume
(PRV) encompassing the medial sagittal plane of the prostate.
The dimensions would be designed to encompass the possi-
ble range of motion of the urethra due to translations and
TABLE II. Percentage of naturally occurring changes in prostate tilt due to
biological motion that fall below the change observed due to removing the
Foley catheter, as illustrated in Fig. 3 for the right-most column in this table.
Prone patient are denoted, p#, and supine patients are denoted, s#. Results
are shown based on tracking data from one fraction and all five fractions, and
looking at the changes in orientation over 1 and 2 min intervals. Results out-
side the 95% confidence interval are in bold and are independent of time
interval or number of fractions.
Patient
One fraction All (five) fractions
1-min interval 2-min interval 1-min interval 2-min interval
p1 0.0 0.0 0.1 0.0
p2 100.0 100 100.0 100.0
p3 0.1 0.0 0.2 0.2
p4 0.0 0.0 0.0 0.0
p5 99.4 99.1 99.8 99.7
p6 3.4 4.6 5.7 8.6
p7 100.0 100.0 100.0 100.0
p8 5.6 9.8 6.5 10.3
p9 0.0 0.0 0.0 0.0
p10 9.8 16.9 3.1 5.6
p11 0.0 0.0 0.3 0.2
s1 59.1 69.4 37.1 32.2
s2 38.2 41.1 34.0 32.1
s3 100.0 100.0 100.0 100.0
s4 57.0 58.8 57.5 59.6
s5 0.0 0.0 0.0 0.0
s6 36.2 46.8 33.6 38.1
s7 100.0 100.0 100.0 100.0
s8 82.8 76.8 89.6 86.6
s9 100.0 100.0 100.0 100.0
s10 100.0 100.0 100.0 100.0
s11 29.2 21.1 27.5 23.1
Medical Physics, 45 (4), April 2018
1374 Litzenberg et al.: Changes in Prostate Orientation 1374
FIG. 3. Histograms of the tilt angle (degrees) of all patients relative to the TPCT (vertical mark at zero). The tilt angle of the FCT is shown by the vertical mark
near or away from zero for each patient. [Color figure can be viewed at wileyonlinelibrary.com]
FIG. 4. This figure shows the initial tilt at the beginning of each fraction as measured relative to the TPCT (solid triangles). The values are shifted by the change
in tilt measured between FCT and TPCT (outlined triangles) to illustrate the number that would have been out of tolerance relative to the FCT.
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FIG. 5. Dosimetric impact on the urethra of the maximum allowed rotations. Change in the dosimetric coverage of the (a) urethra Dmax relative to initial plan val-
ues when rotated +15° (+) and 15° (). Figure (b) shows the planned (o) and rotated (+ and ) urethral V105% values with the <20% planning constraint.
FIG. 6. Dosimetric impact on the CTV and PTV of the maximum allowed rotations. Change in the dosimetric coverage of the (a) CTV D99%, (b) CTV D95%, and
(c) PTV D95% relative to the prescription dose when rotated +15° (+) and 15° ().
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rotations and apply the desired dosimetric planning con-
straints to this structure to avoid excessive urethral dose.
Additionally, investigators have demonstrated the ability to
generate accurate urethral contours with the use of MRI.30 It
is important to note that moderate dose per fraction (7.5 Gy
or less) does not result in high rates of urinary toxicity,2 and
some investigators have suggested the need to keep hotspots
well above these dose ranges (~47 Gy).31 In these cases, one
could safely omit the Foley catheter if hotspots are avoided in
the prostate, especially in the midplane/transitional zone.
However, if dose escalation to >8 Gy per fraction is used,
urethral delineation likely becomes of increased importance.
While the focus of this work has been on the change in
rotation caused by removing a Foley catheter, it should also
be noted that changes in prostate position were also observed
relative to the bones. The observed shifts (average  stan-
dard deviation [min  max]) were: LR = 0.05  0.53
[1.28  0.95] cm, AP = 0.20  0.84 [2.52  1.13]
cm, SI = 0.03  1.28 [4.54  1.67] cm. Because these
shifts in position can be very large relative to the surround-
ing anatomy, it is strongly recommended that planning
should not be done on the FCT if the patient will not be
treated with the Foley in place. While daily image or electro-
magnetic guidance would ensure acceptable dose to the target
volume, the dose delivered to the neighboring organs at
risk (e.g., rectum, bladder, femoral heads, penile bulb) are
likely to be very different than calculated during treatment
planning.
Regarding the statistical data analysis, no corrections were
made for the time correlation of consecutive measurements
of the tilt of the prostate, or its change over 1 or 2-min inter-
vals. It is also unclear how valid it is to combine the changes
in rotation observed between different treatment fractions.
However, from Table II, it can be seen that the results are
independent of the time interval (1 vs 2 min) between the
two CT scans. It is also independent of whether one or five
fractions of tracking data are used to determine the range of
normal changes in tilt that would be expected from biological
motion.
5. CONCLUSIONS
Removing a Foley catheter can cause large prostate
rotations (1.1°  6.0° for prone vs 0.3°  7.4° supine
patients), predominately about the LR axis, compared to nor-
mal biological changes in rotation (P = 5.6 9 109 for prone
vs P = 1.1 9 104 for supine). Consequezntly, the TPCT is a
better representation of the prostate orientation during treat-
ment (in 82% of patients) than the FCT (50% of patients).
Additionally, treatment planning optimization criteria may be
employed to limit hot spots in the urethra experienced over
the range of rotation allowed by protocol tolerances (15°)
while maintaining acceptable CTV coverage. This is espe-
cially true when using dose per fraction of <7.5 Gy/frac-
tion 9 5 fractions. Doses higher than 8 Gy 9 5 may benefit
from a pseudo-urethral PRV or MRI registration to limit dose
to the urethra. Given the inherent risks and discomfort with
the Foley catheter placement, the need for extra dose and time
from a second CT simulation scan, and the ability of treat-
ment planning optimization to mitigate the dosimetric impact
of rotations, obtaining one treatment planning scan without a
Foley catheter is recommended.
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